.png)
.png)
2025 Speakers
Monday, November 10th
David Piwnica-Worms, M.D, Ph.D.
“Activating Anti-Cancer Immunity with Beta-Radioligand Therapy and Isoform-Selective Targeting of 4Ig-B7-H3”
University of Texas, MD Anderson Cancer Center
​
Annapoorna Venkatachalam, PhD, MS
“PARP Inhibitor Resistance: Mutation, Adaptation, and Survival“
Mayo
​
Laura Wood, MD, PhD
“3D Genomic Analysis of Human Pancreatic Precancer”
John Hopkins University School of Medicine
​​
Maggie Mullen, MD
“Targeting the COP9 signalsome overcomes platinum resistance in ovarian cancer through two distinct genome stability mechanisms“
WashU Medicine
​​
Charles Ishak, PhD
“Contributions of chronic viral mimicry towards ovarian high grade serous carcinoma initiation”
University of Texas MD Anderson Cancer Center
​​
Matt Block, MD, PhD
“A Th17 dendritic cell vaccine for ovarian cancer patients”
Mayo Clinic
​​
Mohammed Dwidar, PhD
"Engineering Microbes to Target and Reshape the Ovarian Tumor metabolic landscape"
Cleveland Clinic Foundation
​​
Joan Walker, MD
“Developing Consensus on the Management of STIC Lesions to plan for a Clinical Trial”
University of Oklahoma
​
Gottfried Konecny, MD
"Development of a Claudin 6 targeting Antibody Drug Conjugate: From Bench to Bedside and Back"
University of California Los Angeles
Tuesday, November 11th
Zachary Watson, PhD
"Hematopoietic stem cell derived adipocytes influence the ovarian cancer microenvironment"
University of Colorado AMC
​
Becky Stone, MD, MS
“Ovarian Cancer Prevention: Moving From Paradigm Shift To A National Standard of Care”
Johns Hopkins Medicine
​​​​​
Dineo Khabele, MD, FACOG, FACS
“Personal Perspective on Advances in Ovarian Cancer Care and Research“
WashU Medicine
​
Matt Knarr, PhD
"'Nervous in the service' TRPV1+ tumor innervation as a novel driver of ovarian cancer progression"
UPenn Medicine